Are we focused on the wrong risk type in genetic screening? Breast cancer screening study shows new paths to population screening

Kaklamani: The San Antonio Breast Cancer Symposium will focus on deescalating treatment while maintaining outcomes

The San Antonio Breast Cancer Symposium will focus on doing the same with less—less surgery, less radiation, while maintaining clinical outcomes. The symposium will take place Dec. 10-13 in San Antonio, TX.

A clinic at Fred Hutch addresses sexual health needs of patients with breast cancer
Data indicate low adherence to ASCO guideline

New data indicate that, professional guidelines notwithstanding, doctors rarely address concerns about sexual health when they treat women with cancer.

November 15, 2024

Vol.50 No.43

By Claire Marie Porter

In Brief

Fred Hutch, UW, and Seattle Children’s consortium researchers receive $1.7M from Breast Cancer Research Foundation

Six Fred Hutch/University of Washington/Seattle Children’s Cancer Consortium scientists received $1.7M in grants from Breast Cancer Research Foundation to launch or continue studies aimed at improving outcomes in breast cancer.

November 15, 2024

Vol.50 No.43

Drugs & Targets

Mainz Biomed and Thermo Fisher collaborate to develop next-gen global CRC screening product

Mainz Biomed, a molecular genetics diagnostic company specializing in the early detection of cancer, announced a collaborative agreement with Thermo Fisher Scientific Inc. through its subsidiary Life Technologies Corporation.

November 15, 2024

Vol.50 No.43

Clinical Trials & Tribulations

A study measures the long-term downside of prostate cancer screening
A paper in JAMA Oncology focuses on the harms of overscreening, overdiagnosis, and overtreatment

In this week’s issue of JAMA Oncology, there is an important paper that provides information concerning the long-term adverse effects and complications of prostate cancer screening and treatment. xxx:more

Long-term risks from prostate cancer treatment detailed in new report

A new report says those considering PSA screening need such quantitative information on risks and benefits of treatment if they are to make truly informed decisions. Yet leading guidelines do not provide specific estimates of risk. The risks of adverse effects and complications from treatment for prostate cancer are substantial and continue for years after...

November 08, 2024

Vol.50 No.42

Are we focused on the wrong risk type in genetic screening?

Breast cancer screening study shows new paths to population screening

YOU MAY BE INTERESTED IN

Kaklamani: The San Antonio Breast Cancer Symposium will focus on deescalating treatment while maintaining outcomes

A clinic at Fred Hutch addresses sexual health needs of patients with breast cancer
Data indicate low adherence to ASCO guideline

Fred Hutch, UW, and Seattle Children’s consortium researchers receive $1.7M from Breast Cancer Research Foundation

Mainz Biomed and Thermo Fisher collaborate to develop next-gen global CRC screening product

A study measures the long-term downside of prostate cancer screening
A paper in JAMA Oncology focuses on the harms of overscreening, overdiagnosis, and overtreatment

Long-term risks from prostate cancer treatment detailed in new report

Renew today!

Subscriber content

Never miss an issue!

Login

Are we focused on the wrong risk type in genetic screening?

Breast cancer screening study shows new paths to population screening

YOU MAY BE INTERESTED IN

Kaklamani: The San Antonio Breast Cancer Symposium will focus on deescalating treatment while maintaining outcomes

A clinic at Fred Hutch addresses sexual health needs of patients with breast cancerData indicate low adherence to ASCO guideline

Fred Hutch, UW, and Seattle Children’s consortium researchers receive $1.7M from Breast Cancer Research Foundation

Mainz Biomed and Thermo Fisher collaborate to develop next-gen global CRC screening product

A study measures the long-term downside of prostate cancer screeningA paper in JAMA Oncology focuses on the harms of overscreening, overdiagnosis, and overtreatment

Long-term risks from prostate cancer treatment detailed in new report

Never miss an issue!

Login

A clinic at Fred Hutch addresses sexual health needs of patients with breast cancer
Data indicate low adherence to ASCO guideline

A study measures the long-term downside of prostate cancer screening
A paper in JAMA Oncology focuses on the harms of overscreening, overdiagnosis, and overtreatment